Sterling Capital Management’s Pacira BioSciences PCRX Stock Holding History

Sterling Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$337K	Buy	13,292 +2,022	+18%	+$47.8K	0.01%	989
2026 Q1	$255K	Sell	11,270 -6,864	-38%	-$153K	﹤0.01%	1070
2025 Q4	$469K	Buy	18,134 +393	+2%	+$9.35K	0.01%	959
2025 Q3	$457K	Buy	17,741 +1,776	+11%	+$43.6K	0.01%	982
2025 Q2	$382K	Buy	15,965 +410	+3%	+$10.3K	0.01%	1048
2025 Q1	$387K	Buy	15,555 +14,192	+1,041%	+$340K	0.01%	967
2024 Q4	$25.7K	Buy	1,363 +1,208	+779%	+$21.2K	﹤0.01%	1801
2024 Q3	$2.33K	Buy	+155	New	+$2.65K	﹤0.01%	2119
2015 Q4	–	Sell	-7,545	Closed	-$310K	–	1021
2015 Q3	$310K	Buy	+7,545	New	+$462K	﹤0.01%	860
2015 Q1	–	Sell	-2,949	Closed	-$261K	–	941
2014 Q4	$261K	Buy	2,949 +79	+3%	+$7.47K	﹤0.01%	858
2014 Q3	$278K	Buy	+2,870	New	+$279K	﹤0.01%	827

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's PCRX Position: Q2 2026 in Review

Sterling Capital Management increased its Pacira BioSciences (PCRX) stake by 18% in Q2 2026, buying an estimated $47.8K and bringing the position to 13,292 shares worth $337K. The position accounts for 0.01% of the portfolio, ranked #989.

Sterling Capital Management first reported a position in PCRX in Q3 2014 and has held it in 11 quarters since. The position peaked at $469K in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Sterling Capital Management held 13,292 shares of Pacira BioSciences worth $337K as of Q2 2026.
Sterling Capital Management bought 2,022 Pacira BioSciences shares in Q2 2026, an estimated $47.8K.
Pacira BioSciences made up 0.01% of Sterling Capital Management's portfolio in Q2 2026, its #989 holding.
Sterling Capital Management first reported a position in Pacira BioSciences in Q3 2014 and has held it in 11 quarters since.
Sterling Capital Management's Pacira BioSciences position peaked at $469K in Q4 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.